How inflammation affects blood cell development and disease in chronic myelomonocytic leukemia
Official title: The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11036287 · Data updated 2026-11-12
This study is looking at how inflammation affects chronic myelomonocytic leukemia (CMML) and why some patients might see their condition get worse or change into a different type of leukemia, with the hope of finding better ways to manage the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | March 7, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $522,013 |
| NIH project number | 5R01CA278300-03 |
| Project ID | NIH-11036287 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with chronic myelomonocytic leukemia, particularly those experiencing disease progression.
✕Less likely to help
Patients with other types of leukemia or those who are asymptomatic without a diagnosis of CMML may not benefit from this research.
What this research studies
This research investigates the role of inflammation in the progression of chronic myelomonocytic leukemia (CMML), a serious blood cancer. It focuses on how inflammatory conditions can influence the composition of hematopoietic stem and progenitor cells, which are crucial for blood cell formation. By studying these changes, researchers aim to understand why some patients experience a worsening of their condition or transformation into acute myeloid leukemia (AML). The approach includes analyzing patient samples and using preclinical models to replicate findings, which could lead to new insights into disease management.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for monitoring and treating patients with chronic myelomonocytic leukemia.
How similar studies have gone: Other research has shown promising results in understanding the role of inflammation in blood cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Padron, Eric — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Padron, Eric
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for a blood cancer called CMML (CBL-mutant CMML)
A physician-scientist is testing targeted drugs to treat a hard-to-kill blood cancer called CMML in patients whose cancer has CBL mutations.
-
Understanding how CMML develops and becomes aggressive
Looks at blocking overactive MEK/ERK signals and BET protein-driven gene activity to slow or reverse aggressive CMML and lower its chance of turning into AML for people whose leukemia has NRAS and ASXL1 mutations.
-
Blocking PLK1 in RAS‑mutated chronic myelomonocytic leukemia
People with relapsed or refractory proliferative CMML that has RAS pathway mutations will receive an oral drug called onvansertib that blocks the cell‑division protein PLK1 to look for safety and early signs of benefit.
-
How inflammation changes blood stem cells and drives progression in chronic myelomonocytic leukemia
Looking at whether inflammation changes blood stem cells and speeds disease in adults with CMML.
-
Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia
Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.
-
Understanding how chronic myelomonocytic leukemia resists targeted therapy
This study is looking at how some people with chronic myelomonocytic leukemia (CMML) might not respond to a treatment called cobimetinib, and it aims to help those patients by figuring out why that happens and finding better ways to treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.